According to a 2020 Biotechnology Innovation Organization report, fewer than 8% of drug candidates that enter clinical trials eventually receive regulatory approval. One of the primary reasons for this high failure rate is the poor translatability of preclinical findings, often due to a lack of appropriate mouse models.

This guide explores key considerations for generating and managing genetically engineered mouse models (GEMs) to accelerate and optimise preclinical research programmes.

  • Generating GEMs: three cutting-edge technologies you need to know.
  • Five key components of effective colony management.
  • How integrated solutions can unlock the full potential of preclinical research.

Download the eBook.